Our work on NRTIs and Alzheimer's disease was highlighted today in the Wall Street Journal op-ed "You Can Teach an Old Drug New Tricks," and in the policy report it links to from the University of Chicago & Duke Margolis Institute on pull funding for generic drug repurposing.
wsj.com/opinion/you-can-teac…
Across 270,000 patients in two major health databases, NRTIs are HIV drugs that also block inflammasomes and cut Alzheimer's risk by 6-13% per year of treatment, potentially preventing ~1 million new cases annually (Alzheimer's & Dementia). The same inflammasome biology drives diabetes too, where NRTIs reduce risk by 33% (Nature Communications).
The next chapter: K8 and K9, our next-gen inflammasome inhibitors (Kamuvudines), are the direct descendants of this work, safer, more potent, and already in clinical trials.
UChicago/Duke Margolis pull funding report:
marketshaping.uchicago.edu/w…
UVA Health on NRTIs & Alzheimer's disease:
uvahealth.com/news/hiv-drugs…
UVA Health on NRTIs & diabetes:
uvahealth.com/news/hiv-drugs…